Navigation Links
MINRAD International, Inc. Announces 2007 Financial Results
Date:3/31/2008

h and cash equivalents - end of year $238 $4,664

MINRAD INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except number of shares)

Series A Addi-

Convertible tional Accum-

Preferred Stock Common Stock Paid-in ulated

Shares Amount Shares Amount Capital Deficit Total

Balance at

December

31, 2005 11,200 $3 29,058,431 $290 $40,262 $(36,209) $4,346

Sale of

common

stock,

net of

costs - - 11,500,000 115 34,397 - 34,512

Conversion

of

preferred

stock and

accrued

dividends

to common

stock

(11,200) (3) 5,677,666 57 129 - 183

Preferred

stock

dividends - - - - - (669) (669)

Stock

warrants

exercised - - 564,213 6 469 - 475

Stock

options

exercised - - 247,930 2 415 - 417

Stock

based

compen-

sation - - - - 841 - 841

Net loss - - - - - (6,603) (6,603)

Balance at

December

31, 2006 - $ - 47,048,240 $470 $76,513 $(43,481) $33,502

Stock

warrants

exercised - - 1,121,047 12 2,260 - 2,272

Stock

options

exercised - - 519,515 5 962 - 967

Stock based

compen-

sation - - - - 1,134 - 1,134

Net loss - -
'/>"/>

SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
2. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
3. MINRAD International, Inc. to Discuss 2007 Fourth Quarter and Full Year Financial Results on Monday, March 31, 2008
4. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
5. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
6. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
7. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
8. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
9. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
10. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
11. Chindex International, Inc. Announces Transfer to NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Skincare Industry Newcomer Shines 51058 1Skincare Industry Newcomer Shines 51058 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 1For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 3Allied World Schedules Second Quarter 2009 Earnings Announcement and Conference Call 51052 1